If phase III data confirm survival benefits, dual PD-1/L1 and VEGF blockade may replace PD-L1 monoclonal antibodies as the new frontline standard for SCLC, while providing a high-response-rate, chemotherapy-free option for second-line therapy. Here, VEGFA is linked to small cell lung carcinoma.